LIVEMarkets rolling coverageStarted: July 28, 2026, 4:00 AM EDTUpdated: July 29, 2026, 3:59 AM EDT CSL Jumps 3.5% as Horizon 2 Clinical Trial Pathways Announced July 29, 2026, 3:59 AM EDT. CSL Limited (ASX:CSL) shares rose 3.5% to A$123.68 after the biotechnology firm unveiled fresh clinical trial pathways for Horizon 2. The update marks a step forward for the company’s research pipeline, boosting investor confidence during early session trading. CSL shares rise as Horizon 2 clinical trial pathway takes shape Janus Henderson US Transformational Growth High Conviction Equity UCITS ETF Posts NAV Figures July 29, 2026, 3:46 AM EDT. As